NCT04827498

Brief Summary

Coronary-related myocardial ischemia can result from obstructive epicardial stenosis or non-obstructive causes including coronary microcirculatory dysfunction and vasomotor disorders. This prospective study has been created in order to provide knowledge in the field of non-obstructive coronary artery disease.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
57mo left

Started Nov 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress65%
Nov 2017Dec 2030

Study Start

First participant enrolled

November 8, 2017

Completed
3.4 years until next milestone

First Submitted

Initial submission to the registry

March 25, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 1, 2021

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2030

Expected
Last Updated

April 26, 2021

Status Verified

April 1, 2021

Enrollment Period

8.2 years

First QC Date

March 25, 2021

Last Update Submit

April 23, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Patient-oriented composite outcome

    Incidence of a patient-oriented composite outcome, a composite of any death, nonfatal myocardial infarction, any ischemia-driven revascularization or hospitalization due to unstable angina pectoris

    Up to 5 years

  • Vessel-oriented composite outcome

    Incidence of a vessel-oriented composite outcome, a composite of cardiac death, target-vessel related myocardial infarction or target-vessel revascularization

    Up to 5 years

  • Patient symptoms burden

    Change in the Seattle questionnaire of angina scoring, associated to stratified medical treatment. Minimum is 0 and maximum is 100 and lower scores indicate worse outcome

    Up to 12 months

Secondary Outcomes (6)

  • Cumulative incidence of any death

    Up to 5 years

  • Cumulative incidence of cardiac death

    Up to 5 years

  • Cumulative incidence of nonfatal myocardial infarction

    Up to 5 years

  • Cumulative incidence of ischemia-driven revascularization

    Up to 5 years

  • Safety of invasive comprehensive coronary functional testing with adenosine and acetylcholine

    During procedure

  • +1 more secondary outcomes

Other Outcomes (13)

  • Resting and hyperemic mean aortic pressure (mmHg)

    During procedure

  • Resting and hyperemic mean intracoronary distal pressure (mmHg)

    During procedure

  • Resting and hyperemic mean coronary flow (mean transit time or cms/sec)

    During procedure

  • +10 more other outcomes

Study Arms (1)

Myocardial ischemia without obstructive coronary stenosis

Diagnostic Test: Invasive coronary endothelium-dependent and non-endothelium-dependent physiological assessment

Interventions

Coronary hemodynamics and vessel anatomical measures obtained during adenosine and acetylcholine evaluation with a dedicated physiology wire

Myocardial ischemia without obstructive coronary stenosis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The target population consists of patients with clinically indicated invasive physiological measures of coronary pressure and flow with adenosine and acetylcholine for the assessment of myocardial ischemia.

You may qualify if:

  • Written informed consent available.
  • Age ≥ 18 years.
  • Patient eligible for invasive physiological assessment with adenosine and / or acetylcholine.

You may not qualify if:

  • Hemodynamic instability.
  • Anticipated technical issues for physiology wire measurements.
  • Culprit vessel of acute coronary syndrome
  • Contraindications for adenosine administration.
  • Contraindications for acetylcholine test.
  • Reduced life expectancy (less than 1 year).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Clinico San Carlos

Madrid, 28040, Spain

RECRUITING

Related Publications (2)

  • Mejia-Renteria H, Shabbir A, Nunez-Gil IJ, Macaya F, Salinas P, Tirado-Conte G, Nombela-Franco L, Jimenez-Quevedo P, Gonzalo N, Fernandez-Ortiz A, Escaned J. Feasibility and Improved Diagnostic Yield of Intracoronary Adenosine to Assess Microvascular Dysfunction With Bolus Thermodilution. J Am Heart Assoc. 2024 Nov 19;13(22):e035404. doi: 10.1161/JAHA.124.035404. Epub 2024 Nov 7.

  • Mejia-Renteria H, Wang L, Chipayo-Gonzales D, van de Hoef TP, Travieso A, Espejo C, Nunez-Gil IJ, Macaya F, Gonzalo N, Escaned J. Angiography-derived assessment of coronary microcirculatory resistance in patients with suspected myocardial ischaemia and non-obstructive coronary arteries. EuroIntervention. 2023 Apr 3;18(16):e1348-e1356. doi: 10.4244/EIJ-D-22-00579.

MeSH Terms

Conditions

Myocardial IschemiaAngina Pectoris, VariantMyocardial Bridging

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesVascular DiseasesAngina, UnstableAngina PectorisChest PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsCoronary Vessel AnomaliesHeart Defects, CongenitalCardiovascular AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Hernan Mejia-Renteria, MD, PhD

    Department of Cardiology, Hospital Clinico San Carlos

    PRINCIPAL INVESTIGATOR
  • Javier Escaned, MD, PhD

    Department of Cardiology, Hospital Clinico San Carlos

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hernan Mejia-Renteria, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 25, 2021

First Posted

April 1, 2021

Study Start

November 8, 2017

Primary Completion

December 31, 2025

Study Completion (Estimated)

December 31, 2030

Last Updated

April 26, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will share

The study contemplates the possibility of sharing data with other researchers who have similar objectives. IPD to be shared includes demographic data, vessel characteristics, invasive coronary physiology data and outcome measures, appropriately anonymized.

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
Throughout the development of the study

Locations